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On the morning of July 22, 2011, many friends and admirers of
Chief Judge Rader gathered at the University of Washington’s
High Technology Protection Summit to focus on the Chief Judge’s
many important opinions written during his more than 20 years on
the Court of Appeals for the Federal Circuit. The morning
consisted of two lengthy sessions following a keynote speech by a
former student of mine, now a very experienced patent judge, the
Honorable Marilyn L. Huff. The morning concluded with an
address by the President of the University of Washington, Michael
K. Young. Because President Young was instrumental in making
the Chief Judge a permanent member of The George Washington
University Law School faculty, his talk was the perfect capstone to
the morning’s events. Much of the afternoon was focused on Chief
Judge Rader’s influence on the patent laws of countries other than
the United States.
Many of the speakers were kind enough to prepare formal
remarks for the conference, and these papers form the basis for this
festschrift. They include two excellent papers on the Chief Judge’s
influence on foreign patents law, one by Esther H. Lim, a former
law clerk to Chief Judge Rader, dealing with Chinese patent law.
The second, by Kaoru Kuroda and Eiji Katayama, discusses an
important aspect of Japanese patent law. In addition, the papers
include an article by Professor Robert W. Gomulkiewicz
approving of the reasoning of an important contract law opinion
written by the Chief Judge. However, I will focus this introduction
*
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on the papers that deal with the role of the Chief Judge in the
development of American patent law doctrine.
I turn first to Professor Peter Lee’s analysis of what he calls
“Antiformalism.” He finds evidence of Antiformalism in various
decisions of the Chief Judge, but I suspect the record is more
complicated because the Chief Judge believes in giving sound
guidance to the public by means of easily understood rules so as to
minimize legal costs. For example, is his opposition to the Federal
Circuit’s written description requirement for originally filed claims
an example of Antiformalism or simply a questioning of why a
new, vague, and unneeded requirement was added for originally
filed claims? I believe it is the latter. Indeed, I do not believe any
opinion of the Federal Circuit has answered his critique of using
written description for originally filed claim as an added
requirement alongside enablement.
Another general topic is the one treated by Judge Huff: the
appropriate use of experts in patent cases. This is an area that the
Chief Judge has covered extensively in a number of opinions
including those written while sitting as a trial judge by designation.
It fits in with his intense interest in claim construction and damage
law. Judge Huff’s article also gives the reader an inside view of
how the jurisprudence of the Chief Judge has impacted the patent
trial work of a distinguished district judge with a heavy patent
docket.
Turning now to obviousness, the article by Professor Mark D.
Janis is instructive in showing how obviousness considerations
have impacted the Federal Circuit’s utility and written description
jurisprudence. The Chief Judge realized many years ago that In re
Deuel 1 was wrongly decided and needed to be overturned. He said
as much in his dissent in In re Fisher, 2 where he had the better
argument, but politically the other panel members had no choice
but to use the utility doctrine to invalidate the plainly obvious
claims before the court. In addition, Professor Janis believes that
the Federal Circuit has developed the written description doctrine
for originally filed claims as another counterweight to In re Deuel.
1
2

51 F.3d 1552 (Fed. Cir. 1995).
421 F.3d 1365 (Fed. Cir. 2005).
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This is probably the case, although one that is hard to prove. In any
event, it was the Chief Judge himself who finally laid In re Deuel
to rest by invoking KSR 3 in In re Kubin. 4
Professor Janis also reviews In re Translogic, 5 where the Chief
Judge explained that any prior art reference and its obvious
variations invalidates a claim that reads on any of its obvious
variations. He carefully explained that this was the original error
made by the Federal Circuit in KSR. However, the Chief Judge’s
role in Dystar Textilfarben GmbH v. C.H. Patrick Co., 6 which
issued shortly before the oral argument in KSR, was also extremely
important in the modern development of obviousness
jurisprudence. Dystar served as a vehicle for the Federal Circuit to
explain to the Supreme Court how it should interpret both its own
precedents and those of the Federal Circuit. The opinion was
drafted by then-Chief Judge Paul Redmond Michel, with only
Chief Judge Rader joining in the opinion. In explaining both lines
of cases, Dystar made them look as good as possible. In essence,
this was an amicus brief by Judges Michel and Rader that was
carefully and wisely followed by Justice Kennedy. Indeed, while
the Supreme Court is not a court that corrects errors, but rather
deals with policy, after reading Dystar Justice Kennedy essentially
left the policy set forth in its interpretation or rendition of the
relevant case law alone and proceeded to fix the error made by the
unpublished opinion in KSR. This may have saved the patent
system from a train wreck.
Turning now to Professor Katherine White’s review of a
number of the Chief Judge’s infringement decisions, I want to
comment specifically on his concurring opinion in Johnson &
Johnston. 7 I believe this is the best-reasoned opinion ever written
anywhere in the world on the doctrine of equivalents. It actually
explains when a sound patent system should permit non-textual
infringement. Moreover, it was issued on March 28, 2002, and the
3

KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007).
561 F.3d 1351 (Fed. Cir. 2009).
5
In re Translogic Tech., Inc., 504 F.3d 1249 (Fed. Cir. 2007).
6
464 F.3d 1356 (Fed. Cir. 2006).
7
Johnson & Johnston Assoc. v. R.E. Service Co., Inc., 285 F.3d 1046 (Fed.
Cir. 2002).
4
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Supreme Court decided Festo Corp. v Shoketsu Kinzoku Kogyo
Kabushiki Co. 8 on May 28, 2002, precisely two months to the day
later. Justice Kennedy’s opinion tracks the Chief Judge’s
concurring opinion with respect to when a patentee may overcome
a prosecution history estoppel except on one relatively small point.
The Supreme Court would permit the use of the doctrine of
equivalents with respect to a claim limitation even where an
estoppel existed if adding the claim limitation was “tangential.” In
addition, of course, the Supreme Court following its own
precedents divided the doctrine of equivalents question into two
categories. In one, there is a prosecution history estoppel. In the
other, there is no estoppel. The concurring opinion would make no
such distinction, a distinction which is makes little sense as I have
explained elsewhere. 9 In short, had it followed the Chief Judge
fully, the Court would not have erred by adding “tangential” and
would have eliminated the unwise distinction based on prosecution
history estoppel. But at least the Court went part way toward
developing as the Chief Judge explained a sound doctrine of
equivalents.
I now turn to Professor John M. Golden’s paper on
Therasense. 10 Although mentioned in his sixth footnote, Professor
Golden might have made more of the powerful dissent of the Chief
Judge in Aventis Pharma S.A. v. Amphastar Pharmaceuticals,
Inc. 11 That important case committed one of the great injustices of
modern patent litigation. It involved a claim that a leading French
scientist, Dr. Andre Uzan, intentionally and with the intent to
deceive failed to disclose the dosage (60 mg) used to test the halflife of a prior art product when he compared it to the half-life of
the claimed product, the very important drug Lovenox. Because
ordinarily at pharmaceutically relevant doses first order chemical
kinetics dictate that the half-life is independent of dosage, it is
8

535 U.S. 722 (2002).
Martin J. Adelman, Patent Claiming in the United States: Central,
Peripheral, or Mongrel?, 1 IP THEORY 71 (May 8, 2012)
http://www.repository.law.indiana.edu/ipt/vol1/iss2/2.
10
Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir.
2011) (en banc).
11
525 F.3d 1334 (Fed. Cir. 2008).
9
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surely understandable that a leading scientist familiar with the art
would not believe it important to reference the dosage when
comparing the measured half-life of a pharmaceutical product at
least at ordinary dosages. Just ask any doctor whether he or she
believes there is a significant difference in half-life for any drugs
used by the doctor at pharmaceutically relevant dosages.
Unfortunately, even though anyone with access to the Internet
could learn about first-order kinetics, the dispute turned on
measuring the half-life of Lovenox at different disclosed dosages
and then measuring the half-life of a prior art composition at an
undisclosed relatively high dosage for the purpose of showing that
the half-life of Lovenox was greater than the half-life of the prior
art formulation. From the prospective of the patent applicant, the
lower the half-life of the prior art composition the better the test
would look with respect to patentability. Since the withheld dose
was on the high side, it was either irrelevant, the most likely
situation, or it made the test appear slightly worse for the purposes
of patentability as at some point increasing the dosage overloads
the body and therefore causes a departure from first order kinetics,
thereby increasing the measured half-life. However, given the
variability of tests for half-life, some internal company data
showed that the half-life at 40 mg when measured was greater than
at 60 mg for the prior art product. A knowledgeable scientist would
know that this result was most likely the result of experimental
variation and not an underlying characteristic of the products and
hence would not believe that the prior art dosage level was
important.
In any event, the Chief Judge sensed that there was no reason
for Dr. Uzan to deceive the USPTO and risk besmirching his
distinguished reputation. As a result, he wrote a powerful opinion
on intent. Of course, he was correct as I am sure that Dr. Uzan is
wondering what is the matter with the education of Americans that
they do not know about first-order kinetics in chemistry or that
half-life is usually constant over the range of pharmaceutical doses.
While the Federal Circuit did not correct the manifest injustice of
its Aventis Pharma opinion by going en banc and reversing, it did
try and make amends in Star Scientific, Inc., v. R.J. Reynolds
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Tobacco Co. 12 and ultimately in Therasense. Unfortunately while a
reading of the full opinion of the Board of Appeal in the European
Patent Office discussing the prior art reference in Therasense
shows that there was no conflict between the record in the USPTO
and the proceedings in the USPTO, even after the en banc
Therasense opinion, a true tour de force, Judge Alsup remained
unmoved and found “inequitable conduct” under the new
standards. 13 Whether Therasense will make the hoped for
correction of inequitable conduct law is for the future. The
implications raised by Judge Alsup’s opinion on remand and the
Federal Circuit’s recent decision in Aventis Pharma S.A. v.
Hospira, Inc. are not encouraging,
In sum, this festschrift covers only a small slice, but an
important one, of the extensive work that the Chief Judge has done
in his judicial career to date. We hope there will be much more
significant judicial work in the future from him.

12

537 F.3d 1357 (Fed. Cir. 2008).
Therasense, Inc. v. Becton, Dickinson & Co., No. C 04-02123 WHA,
2012 WL 1038715 (N.D. Cal. Mar. 27, 2012).
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